What is market sentiment?

Market sentiment is the overall attitude of investors toward a particular security or the financial market as a whole. It reflects whether investors are feeling bullish (optimistic) or bearish (pessimistic) based on price action, news flow, economic indicators, and collective psychology. Kinvestor tracks real-time market sentiment across major indices and individual equities.

How does financial news affect stock prices?

Financial news affects stock prices by shifting investor sentiment. Positive earnings reports, strong economic data, or favorable Fed decisions typically boost stock prices, while negative news can trigger sell-offs. The speed and magnitude of price moves depends on whether the news beats or misses market expectations.

What are stock market movers?

Stock market movers are stocks with significant price changes — either up (gainers) or down (losers) — within a trading session. Movers are typically driven by earnings reports, analyst upgrades or downgrades, macroeconomic news, or major corporate announcements. Kinvestor tracks the biggest movers in real time across the S&P 500, NASDAQ, and Dow Jones.

What is earnings season?

Earnings season is the period each quarter when publicly traded companies report their financial results. It occurs four times per year: January–February (Q4 results), April–May (Q1 results), July–August (Q2 results), and October–November (Q3 results). During earnings season, stocks often experience heightened volatility as results beat or miss analyst expectations.

What is financial intelligence?

Financial intelligence is the ability to understand and interpret financial data, market trends, news, and sentiment to make informed investment decisions. It combines real-time market data, news aggregation, sentiment analysis, and economic indicators into actionable insight. Kinvestor is a financial intelligence platform that aggregates these signals in one place.

◆ NeutralSTTK

Shattuck Labs Announces Phase 1 Results for SL-325

GlobeNewswire Inc.·June 8, 2026

Shattuck Labs announced encouraging Phase 1 clinical trial results for SL-325, its lead DR3 blocking antibody candidate, showing a potentially best-in-mechanism immunogenicity profile with only 3.7% of participants developing antidrug antibodies, complete DR3 blockade at low doses, and a favorable safety profile. The company plans to initiate the RECEPTIVE-CD1 Phase 2b trial in Crohn's disease patients in Q3 2026, with lead bispecific candidate SL-846 expected to enter Phase 1 in H1 2027.

Read Full Article at GlobeNewswire Inc. →

← Back to Financial Intelligence